MyCEI Login


GLP-1 RA and SGLT2i: New Treatment Strategies for Diabetes and Obesity in the Context of HIV


Published Date: 05/17/2024

Expiration Date: 04/15/2027

CE Credit: CME:1


With all the recent advances in the treatment strategies for obesity and for diabetes, it is hard to keep up-to-date, especially if many of your patients are already on antiretroviral regimens for HIV. This presentation by Todd Brown will help you more deeply understand how GLP-1 receptor agonists and SGLT2 inhibitors work, and their efficacy and long-term safety in the treatment of diabetes and obesity in HIV medicine.


Todd T. Brown,MD, PhD

Todd Brown, MD, PhD is the primary endocrine consultant to the Johns Hopkins HIV Clinic. His research focuses on metabolic, endocrine, and skeletal abnormalities observed in HIV-infected patients. He is the co-chair of the Executive Committee of the MACS WIHS Combined Cohort Study and has served in leadership positions for the ACTG. He has mentored multiple trainees from across the country and around the world in the area of HIV Comorbidities and Aging. He has published widely on the topic of HIV and endocrine conditions and lectures internationally on this and other issues related to metabolic diseases in HIV. 

Learning Objectives

  • Be able to describe how GLP-1 receptor agonists and SGLT2 inhibitors work
  • Know the risks and benefits of GLP-1 receptor agonists and SGLT2 inhibitors and where they fit in for the treatment of diabetes.
  • Understand the impact of GLP-1 receptor agonists for the treatment of obesity and be familiar with unanswered questions about their long-term safety and efficacy.
  • Understand what is known about these medications in people with HIV.

Continuing Education Credit Information